Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Argenx Se ADR (NQ: ARGX )

596.74 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Argenx Se ADR

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Argenx Dives On Autoimmune Therapy Failure
A treatment for a skin-blistering condition failed to beat a placebo. 
Via Investor's Business Daily
FedEx Posts Downbeat Earnings, Joins Steelcase, argenx And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
U.S. stock futures were lower this morning, with the Dow Jones futures falling around 30 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
argenx Reports Topline Results from ADDRESS Study of Efgartigimod SC in Pemphigus
From argenx SE
Via GlobeNewswire
Stifel Maintains Buy Rating for argenx: Here's What You Need To Know
Via Benzinga
Here's How Much $1000 Invested In argenx 5 Years Ago Would Be Worth Today
Via Benzinga
Analyst Ratings for argenx
Via Benzinga
These 2 Stocks Are Falling in a Fading Rally
It's been a good month, but the stock market's looking tired. 
Via The Motley Fool
$1000 Invested In argenx 5 Years Ago Would Be Worth This Much Today
Via Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $5,000 Today
Via Benzinga
Dow Jones Hits 2023 High, Nasdaq Slips; Tesla Cybertruck, Salesforce In Focus: Weekly Review
Software earnings were strong, while the Fed is shifting toward rate cuts. 
Via Investor's Business Daily
Topics Economy Stocks
Exposures Interest Rates US Equities
Morgan Stanley Maintains Overweight Rating for argenx: Here's What You Need To Know
Via Benzinga
Micron To Rally Around 12%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Earnings Outlook For argenx
Via Benzinga
Here's How Much You Would Have Made Owning argenx Stock In The Last 5 Years
Via Benzinga
Why SenesTech Shares Are Trading Lower By Around 50%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of SenesTech, Inc. (NASDAQ: SNES) shares moved lower during Tuesday’s session after the company reported pricing of $5.0 million public offering. 
Via Benzinga
Why Is Dutch Pharma Argenx Trading Lower Today?
Tuesday, Argenx SE (NASDAQ: ARGX) released topline results from the ADVANCE-SC study evaluating Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) in adults with primary immune thrombocytopenia... 
Via Benzinga
Argenx Stock Crashes On An Unexpected Failure For Its Biggest Drug
The company was hoping its drug would make a difference for patients with a rare blood disorder. 
Via Investor's Business Daily
Why SpringWorks Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket
Shares of SpringWorks Therapeutics, Inc. (NASDAQ: SWTX) surged in pre-market trading after the company reported the FDA approval of OGSIVEO (nirogacestat) as the first and only treatment for adults... 
Via Benzinga
Exposures Product Safety
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to dive into the biggest pre-market stock movers for Tuesday morning with all of the latest news you need to know today! 
Via InvestorPlace
Zscaler Posts Q1 Results, Joins argenx, Cool Company And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures traded mixed this morning, with the Dow Jones futures gaining around 15 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
argenx Reports Topline Results from ADVANCE-SC Study of VYVGART Hytrulo in Primary Immune Thrombocytopenia
From argenx SE
Via GlobeNewswire
Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst
Wedbush initiated coverage on Dianthus Therapeutics Inc (NASDAQ: DNTH), noting its lead program DNTH103 as a well-positioned monoclonal antibody directed against the active form of the  
Via Benzinga
argenx Announces European Commission Approval of Subcutaneous VYVGART® (efgartigimod alfa) for Generalized Myasthenia Gravis
From argenx SE
Via GlobeNewswire
Tech Titans Rising: 7 Underrated Stocks Set for Explosive Growth
Are you looking to invest in rising tech stocks? Here are seven underrated stocks set for explosive growth. 
Via InvestorPlace
Stock Market Rally Back In Force As Treasury Yields Plunge; Arista, Palantir Among Winners: Weekly Review
Bulls are back in control as the major indexes confirmed the uptrend this week. 
Via Investor's Business Daily
argenx Highlights Data Evaluating VYVGART in Neuromuscular Autoimmune Disease at AANEM and MGFA Scientific Sessions
From argenx SE
Via GlobeNewswire
argenx to Present at Upcoming Investor Conferences
From argenx SE
Via GlobeNewswire
Argenx Comes Up With Big Sales Beat, Narrower-Than-Expected Losses
The company sells Vyvgart, a treatment for generalized myasthenia gravis. 
Via Investor's Business Daily
Topics Earnings
Exposures Financial
argenx Reports Third Quarter 2023 Financial Results and Provides Business Update
From argenx SE
Via GlobeNewswire
argenx to Report Third Quarter 2023 Financial Results and Business Update on October 31, 2023
From argenx SE
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.